Sign in
Taking peopleNo phase

Precision Use of TXA in Intracerebral Hemorrhage

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
70 people, planned
Started
1 Jan 2026
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tranexamic Acid (IV)
Record updated
26 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Primary ICH Diagnosis
  • Age ≥ 18 years
  • Within 6 hours of ICH
  • Supratentorial ICH
  • GCS ≥8
  • Location-specific volume criteria (>7ml for thalamus or internal capsule; >30ml for putamen or lobar)

Who cannot take part

  • Anticipated surgical treatment
  • Receiving anticoagulation
  • Recent acute atherosclerotic cardiovascular diseases (e.g. acute coronary syndrome, ischemic stroke)
  • Bleeding tendency
  • Severe renal impairment
  • Severe liver impairment
  • Known contraindication or allergy to tranexamic acid
  • Severe pre-morbid disability (Pre-morbid modified Rankin scale 5)
  • Recent intravascular stent placement and on dual antiplatelet treatment
  • Expected life expectancy of <1 year
  • Inability to participate in follow-up activity

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Primary Intracerebral hemorrhage (ICH) is a severe and disabling disease. The hematoma will expand within the first few hours, which contributes to increasing brain injury and worsening neurological prognosis. Hence, one of ICH's main acute therapeutic strategies is to reduce hematoma expansion (HE) with hemostatic agents like tranexamic acid (TXA) or recombinant factor VIIa. However, although most HE trials have demonstrated that treatment attenuated HE, they have largely been unable to demonstrate therapeutic benefit in improving functional outcomes. The lack of outcome benefits for ICH treatment is because therapeutic benefits are significantly confounded by the outcome heterogeneity based on ICH location and the variation in the degree of HE between patients, which is not accounted for in all ICH trials.

Read full original descriptionShow less

The investigators' recent work has examined the interplay between ICH location and volume in determining ICH pathophysiology and outcomes, highlighting a critical interaction between these factors and neurological prognosis. Also, as HE only occurs in 15-40% of patients, the therapeutic benefits of treatment targeting HE are not modifiable in most patients. Furthermore, only a minority of patients with HE experienced neurological deterioration (HE-related neurological deterioration) that could impact their neurological outcomes. There is also a location-specific variation in the risk of HE-related neurological deterioration, occurring at a larger baseline volume for ICH at putamen/ lobar compared to thalamus/ internal capsule. Hence, as outcome heterogeneity based on ICH location and the variation in the degree of HE significantly confounds therapeutic effect, better patient selection for hemostatic agents in ICH treatment is essential to yield functional benefit.

To address this, a novel selection criteria (>7ml for thalamus/ internal capsule, >30ml for putamen/ lobar) is proposed, which, in theory, would account for the confounding effect of location-specific outcome heterogeneity and the location-based variation in HE-related neurological deterioration. Therefore, the PRECISE-TRANSACT trial aims to investigate whether TXA administration based on this selection criteria significantly reduces the risk of neurological deterioration and consequent therapeutic benefit.

The 2 groups in the trial

  • TXA armExisting treatment, for comparison

    TXA 1000mg stat over 10 minutes and 1000 mg over 8 hours

    Treatment: Tranexamic Acid (IV)

  • Control armNo study treatment, for comparison

    No TXA

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PRECISion usE of TRANexamic Acid for Supratentorial Acute Cerebral Hemorrhage Trial: a Pilot Randomized Controlled Trial
Record updated
26 January 2026